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ABSTRACT
Objective: Present study aimed to evaluate the antidepressant-like activity of thymoquinone (TQ) in unstressed and stressed condition and to explore 
the possible underlying mechanism for this activity.
Methods: TQ (5, 10, and 20 mg/kg) and fluoxetine per se were administered to the unstressed and stressed mice; immobility periods were observed 
using forced swim test (FST) and tail suspension test (TST). Effect of corticotropin-releasing factor (CRF)-1 antagonist on antidepressant-like activity 
was also evaluated. The mechanism of action was also explored by measuring plasma corticosterone levels.
Results: TQ (20 mg/kg) and fluoxetine per se significantly decreased immobility periods in stressed mice indicating significant antidepressant-like 
activity under stress. There was no significant effect on locomotor activity of the mice on treatment with TQ and fluoxetine per se. It significantly 
decreased plasma corticosterone level. Antalarmin (a CRF-1 receptor antagonist) significantly attenuated TQ induced the antidepressant-like effect 
in both FST and TST.
Conclusion: TQ significantly produced antidepressant-like activity in mice possi-bly through inhibiting CRF activity and decreasing plasma 
corticosterone levels.
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INTRODUCTION
Depression is a mood disorder that affected more than 300 million 
people worldwide and is the most prevalent neuropsychiatric disorder. 
Investigations have demonstrated that depression encompasses a 
profound neurocircuitry failure. The brain regions involved in this 
dysregulation may include the hypothalamus, hippocampus, amygdala, 
and striatum [1,2]. These nuclei are important regulators in endocrine 
control of behaviors symptomatic of depression such as eating, sleeping, 
circadian rhythm, stress response, learning and memory, and pleasure 
seeking [3]. Depression is characterized by persistent sadness and a 
loss of interest in activities that people normally enjoy accompanied by 
an inability to carry out daily activities.
Depression and stress have a strong interlinking and have been well 
established. A key factor in response to stress is the neuropeptide 
corticotropin-releasing factor (CRF) [4]. CRF and its receptors (CRFR1 
and CRFR2) are important regulators of the hypothalamic-pituitary-
adrenal (HPA) axis. Evidence build up knot bridging CRF to the 
development of depression [5-9]. Clinical studies have found increased 
CRF and decreased CRF receptors in postmortem examination of 
suicide victims. In addition, excessive activation of the HPA axis has 
been reported in more than one-half of patients with depression, 
and these symptoms have been corrected during antidepressant 
treatment [7].
During a stress response, the hypothalamus is activated and releases 
CRF (also known as corticotropin-releasing hormone), which stimulates 
the release of adrenocorticotropic hormone (ACTH) from the pituitary 
gland. ACTH induces glucocorticoid synthesis and releases from the 
adrenal/interrenal tissue into the blood [10].
This stress-related neuropeptide acts at the level of the pituitary to 
initiate the HPA axis response stress [4-12]. CRF containing neurons are 
not confined to hypothalamic regions; they are also found in a number 
of neural circuits that mediate information processing and behavior. 
CRF has been shown to modulate diverse neurotransmitter systems 
including glutamate, dopamine, serotonin, and norepinephrine [13-15]. 
Modulation of serotonin and norepinephrine release by CRF supports 
its effective role in depression [16,17].
Thymoquinone (TQ) is the most abundant component of seed oil 
of Nigella sativa. It possesses pharmacological activities including 
analgesic and anti-inflammatory activity [18], protection against 
chemical-induced carcinogenesis [19], inhibition of eicosanoids 
generation, and membrane lipid peroxidation [20]. The effects of TQ 
on central nervous system include neuroprotection [21], suppression 
of epilepsy [22], attenuation of nociceptive response [18], and 
suppression of oxidative stress-induced neuropathy [23]. At the 
molecular level, TQ has been shown to downregulate tumor necrosis 
factor [24] and suppress nuclear factor-kappa B activation in the 
brain and spinal cord [25,26]. TQ significantly reduced protein levels 
of inducible nitric oxide synthase (iNOS) and inhibited an increase in 
iNOS mRNA [23]. Further, TQ has served to enhance the survival of 
pancreatic beta cells by nitric oxide inhibitory mechanism [27]. Further 
TQ, the major constituent of N. sativa seeds, administered by oral route, 
and intracerebroventricular injection exerts anticonvulsant activity 
that is reversed by flumazenil [22,28].
Literature search showed us that there had been no study investigating 
the effect of TQ on depression. This study was aimed to investigate 
the effects of TQ in mice subjected to forced swim test (FST) and tail 
suspension test (TST) and to compare its effects with a conventional 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i11.21773
Research Article
Central University, Bilaspur - 495 009, Chhattisgarh, India. Email: harshi.jain1987@gmail.com
Received: 02 August 2017, Revised and Accepted: 26 September 2017
393
Asian J Pharm Clin Res, Vol 10, Issue 11, 2017, 392-396
 Jain et al. 
SSRI fluoxetine. For determining the effects of the immobilization (IM) 
session and drug therapy, duration of immobility of the animals was 
recorded. At the end of the IM session, TST and FST, which are known 
to be the frequently used and effective methods to evaluate depression, 
were applied to all of the animals to assess the ability of drugs to 
reverse stress-induced effects. This study was designed to investigate 
the potential of TQ as an antidepressant under stress and explore the 
involvement of CRF in mediating its effect.
METHODS
Swiss albino mice (20-25 g) were employed in the study. Animals were 
procured from the DRDE, Gwalior, India. Animals were housed separately 
in groups of 10/cage under laboratory conditions with alternating light 
and dark cycles of 12 hrs each. They had free access to food and water. 
The animals were acclimatized to the laboratory conditions before 
behavioral experiments. Animals were kept fasted 2 hrs before 2 hrs 
before drug administration. The animals were acclimatized for 5 days 
before behavioral experiments which were carried between 8:00 and 
17:00 hrs. The experimental protocol was approved by the Institutional 
Animal Ethics Committee, and care of the animals was taken as per the 
guidelines of the Committee for the Purpose of Control and Supervision 
of Experiments on Animals.
Drugs
The following drugs and chemicals were used in this study: Fluoxetine 
hydrochloride, p-nitroso-N, N-dimethylaniline, TQ, antalarmin (AA) 
hydrochloride (Sigma-Aldrich, St. Louis, USA), boric acid, hydrochloric 
acid, and potassium hydroxide (CDH Ltd., New Delhi).
Laboratory models employed for evaluation of antidepressant 
activity
TST
It is a commonly employed behaviors test to evaluate antidepressant-
like activity. The test was performed according to the method described 
by Steru et al. [29] for evaluating potential antidepressants. The total 
duration of immobility induced by tail suspension was measured 
according to the method described. Mice were suspended on the edge 
of a table 50 cm above the floor with the help of a paper adhesive tape 
placed approximately 1 cm from the tip of the tip of the tail. Immobility 
time was recorded for 6 min period. The mice were considered to 
be immobile only when they hung passively and were completely 
motionless [30].
FST
It is another seldom used behavioral test to evaluate antidepressant-
like activity. FST was proposed as a model to test antidepressant activity 
by Porsolt et al., mice were forced to swim individually in glass jar (25 × 
15 × 25 cm3) containing fresh water up to 15 cm height and maintained 
at 25 ± 3°C. After an initial 2 minutes period of vigorous activity, each 
animal assumed a typical immobile posture. Mice were considered to 
be immobile when it remained floating in the water without struggling, 
making only minimum movements of its limbs, necessary to keep its 
head above the water. The total duration of immobility was recorded 
during the last 4 minutes of the total test duration of 6 minutes. The 
changes in immobility duration were studied after administrating the 
drugs in separate groups of animals [31]. Each animal was used only 
once in this test.
Locomotor activity test
The effect of various treatments on locomotor activity was observed in 
actophotometer (Inco, Ambala, India). The locomotor activity scores for 
each animal were recorded for 10 minutes [32].
Biochemical estimations
CRF
Measurement of CRF levels was performed by enzyme immunoassay 
or ELISA using commercially available kit: Mouse/Rat CRF-HS ELISA 
kit (ALPCO Diagnostics). For determination, the brains were rapidly 
removed from mice after completing behavioral tests and isolated brain 
were weighed and homogenized in 30-fold volume of extraction buffer 
10 mM phosphate-buffered saline (pH 7.2) containing 0.2% Nonidet 
P-40 in an ice bath. It was centrifuged (18360×g, 20 minutes) and the 
supernatant was collected and used for measurement. The procedure 
followed was as described earlier [33,34].
Plasma corticosterone estimation
For corticosterone estimation, blood was withdrawn from tail vein 
of mice immediately before setting the animal free and subjecting 
it to behavioral tests in all the groups. The sampling procedure was 
completed during IM to avoid the extra stress incurred on mice during 
an altogether a new procedure of mouse IM for handling the tail of 
mice. Plasma was separated using cooling centrifuge at 2500 r.p.m. 
(Remi Centrifuge, Mumbai, India) for 10 min. Corticosterone levels 
were estimated in blood plasma by Bartos and Pesez method [35]. 
To 1.0 ml of plasma sample, 1.0 ml of ethanol, and 0.50 ml of 0.10% 
solution of p-nitroso-N, N-dimethylaniline in ethanol were added, 
and the tubes were immersed in ice water for 5 minutes, and then, 
0.50 ml of 0.1 N sodium hydroxide was added. The tubes were 
plugged with cotton-wool, and let to stand at 0°C for 5 hrs, protected 
from light. To the above solution, 2.0 ml of Clark and Lubs buffer for 
pH 9.8 (prepared by mixing 50.0 ml of an aqueous solution of both 
boric acid and potassium chloride with 40.8 ml of 0.20 M potassium 
hydroxide, and diluted to 200 ml with distilled water), 5.0 ml of 
0.10% solution of phenol in ethanol, and 0.50 ml of 1.0 % aqueous 
solution of potassium ferricyanide were added. The tubes were 
kept in water bath at 20 ± 2°C for 10 minutes. The absorbance of 
the solution was read at 650 nm using ultraviolet spectrophotometer 
(Shimadzu-1800).
Experimental design
Sixteen groups of mice were employed in the study. Each group 
consisted of minimum eight mice. Stress was produced in them by 
immobilizing for 6 hrs (8 a.m. - 2 p.m.) by taping all its four limbs and 
trunk on a wooden board [32]. Mice subjected to IM were called as 
stressed mice, and mice not subjected to IM were called as unstressed 
mice and have been mentioned accordingly. Behavioral testing was 
performed carefully in a stepwise manner, i.e. ,mice in each group 
were subjected to three tests [36]: (a) TST, then, a 6 minutes rest in 
home cage, thereafter, (b) locomotor activity test in actophotometer, 
again followed by 6 minutes rest, and then, (c) FST. All the drugs were 
administered intraperitoneally (i.p.) 30 minutes before the behavioral 
testing in unstressed group and immediately before IM in stressed 
group. When combinations of the drugs were employed, pretreatments 
were administered 15 minutes before the administration of the other 
drug. For CRF determination, the brain was rapidly removed from mice 
after behavioral tests.
Statistical analysis
All the results were expressed as mean ± standard error mean. The 
data were analyzed using 1-way ANOVA followed by Tukey’s test for 
multiple comparisons using the software GraphPad InStat. In all tests, 
the criterion for statistical significance was p<0.05.
RESULTS
Study showed that IM stress has marked effect on depression and TQ 
decreased immobility time in stressed condition at 20 mg/kg, but 
in unstressed condition, TQ has no significant effect on immobility 
time. This indicated significant antidepressant effect of TQ under 
stress.
Different treatments provided to stressed group showed different 
effects. AA (10 mg/kg i.p.) administered alone to stressed group, 
significantly decreased immobility time in TST as well FST (Fig. 1). 
unstressed group  didn’t significantly decrease immobility time in 
both behavioural paradigms. A significant decrease in immobility 
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time was observed when AA (10 mg/kg) was administered in 
combination with TQ (10 mg/kg) in the stressed group as compared 
to TQ (10 mg/kg) group. Similarly, when AA (10 mg/kg) and TQ 
(20 mg/kg) were administered together a significant decrease in 
immobility time was observed in both TST as well as FST. As shown 
in Fig. 2, locomotor activities were not affected by treatment with TQ 
alone, but AA increased it, and its combination with TQ (10, 20 mg/kg) 
again restored the counts.
Treatments on the unstressed group did not significantly change 
levels of CRF. As shown in Fig. 3, co-administration of AA (10 mg/
kg) and TQ (10, 20 mg/kg) did not have any significant changes in 
brain levels of CRF as compared to AA (10 mg/kg) alone. Whereas a 
significant decrease in corticosterone levels was found in the group 
treated with AA (10 mg/kg) administered along with TQ 10 mg/kg as 
well as 20 mg/kg as compared to their respective TQ-treated group 
(Table 1).
DISCUSSION
In the present study, TQ (20 mg/kg) administered to mice under 
stressed condition produced significant antidepressant-like activity in 
TST and FST. This is the first study showing on antidepressant effect of 
TQ on IM stress for 6 hrs. The efficacy of TQ was found to be comparable 
with fluoxetine. FST and TST are two commonly used behavioral despair 
models of depression. These models are widely employed in rodents 
to evaluate antidepressant potential through decreasing immobility 
period produced by different classes of antidepressant drugs [29,37]. 
TQ did not show any effect on locomotor activity as compared to the 
vehicle-treated group in unstressed condition as well as an immobilized 
group in stressed condition.
In FST, mice are forced to swim in constrained area which restricts 
their escape that attributes immobility in them. This behavior reflects 
a state of despair which can be reduced by several agents which are 
therapeutically effective in human depression. The TST also induces 
a state of immobility in animals like that in FST. This immobility 
referred as behavioral despair in animals, which is claimed to 
Table 1: Effect of treatments on corticosterone levels
Group Treatment Concentration in pg/ml
Group I Immo 621.2
Group IV TQ 10 483.5*
Group V TQ 20 438.3*
Group VI AA S 381.0*
Group VII AA + TQ 1 86.9**
Group VIII AA + TQ 2 84.9***
Effect of different treatments on plasma corticosterone levels. Values are 
expressed as mean±standard error. Data were analyzed by one-way ANOVA 
followed by Tukey’s post hoc test. F(7,40)=40.90, p<0.0001, *p<0.001 significant 
difference from immobilized group, **p<0.001 significant difference from TQ 
10 mg/kg-treated group, ***p<0.001 significant difference from TQ 20 mg/kg-
treated group. IM: Immobilization, FLU: Fluoxetine, TQ: Thymoquinone, 
AA: Antalarmin. Doses mentioned are in mg/kg
Fig. 3: Effect of different treatments on corticotropin-releasing 
factor level (ng/ml) in stressed mice. n=8 in each group. Values 
are expressed as mean ± standard error. Data were analyzed by 
one-way ANOVA followed by Tukey’s post hoc test, F(7, 40)=5.2; 
p<0.0001, *p<0.01 significant difference from the immobilized 
group. IM: Immobilization, FLU: Fluoxetine, TQ: Thymoquinone, 
and AA: Antalarmin. Doses mentioned are in mg/kg
Fig. 2: The effect of different treatments on locomotor activity in 
stressed mice expressed in locomotor activity counts. n=8 in each 
group. IM: Immobilization, FLU: Fluoxetine, TQ: Thymoquinone, 
and AA: Antalarmin. Doses mentioned are in mg/kg
Fig. 1: (a and b) Effect of different treatments on immobility 
time on stressed mice in forced swim test (FST) as well as tail 
suspension test (TST), n=8 in each group. Values are expressed 
as mean ± standard error. Data were analyzed by one-way ANOVA 
followed by Turkey’s post hoc test, in FST F(7, 40) = 57.06 TST 
F(7,40)=90.46; p<0.0001, *p<0.001 significant difference from 
immobilized group, **p<0.05 significant difference from TQ 
(10 mg/kg)-treated group, ***p<0.05 significant difference from TQ 
(20 mg/kg)-treated group, IM: Immobilization, TQ: Thymoquinone, 
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reproduce a condition similar to human depression [29,38,39]. 
Out of three doses of TQ, 20mg/kg PO produced a most significant 
effect in stressed mice whereas none of the dose of TQ produced 
a significant antidepressant effect in unstressed condition. The 
most effective dose of TQ was therefore employed in further study 
elucidating the mechanism of antidepressant-like activity. Treatment 
with antalarmin a CRF antagonist specifically antagonizing CRF-1 
receptor reversed extended immobility time under stress in both FST 
and TST. TQ and antalarmin coadministered together made the belief 
stronger by declining immobility time and exerting a direct effect 
on plasma corticosterone. The most astonishing part was that brain 
CRF level remained untouched apart from these rapid combinations. 
Synergizing effect of TQ and antalarmin suggested that TQ may exert 
its effect by cooperating its coadministered drug and antagonizing 
CRF receptors.
Major depression has been linked with hyperactivity of the HPA 
axis [40]. High concentrations of blood glucocorticoid are maintained 
in patients with depression due to the dysfunction of this feedback 
mechanism [41]. High glucocorticoid levels cause pathological damage 
to the hippocampal neurons both in vitro and in vivo [42,43] and 
can induce depression-like behavior in animals [41,43]. Our results 
demonstrated TQ significantly reduced the plasma corticosterone 
levels, by directly acting on CRF receptors. Hence, the antidepressant-
like action shown by the TQ may be due to inhibition of corticosterone 
production and CRF antagonism.
CONCLUSION
Our present study shows that TQ showed significant antidepressant-
like activity in stressed mice probably by interaction with CRF-1 
receptor as it reduced plasma corticosterone levels. Therefore, TQ can 
be explored further for its potential to treat clinical depression.
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